Carfilzomib

What it is used for

Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone.

( 1, 14 ) as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. ( 1, 14 ) 1.1 Relapsed or Refractory Multiple Myeloma Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with: Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone.

Kyprolis is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Cardiac Toxicities
• Acute Renal Failure
• Tumor Lysis Syndrome
• Pulmonary Toxicity
• Pulmonary Hypertension
• Dyspnea
• Hypertension
• Venous Thrombosis
• Infusion-Related Reactions
• Hemorrhage
• Thrombocytopenia
• Hepatic Toxicity and Hepatic Failure
• Thrombotic Microangiopathy
• Posterior Reversible Encephalopathy Syndrome
• Progressive Multifocal Leukoencephalopathy

Who should not take it

None.

Storing it

Storage and Handling

Unopened vials should be stored refrigerated 2°C to 8°C (36°F to 46°F). Retain in original package to protect from light.